ClinicalTrials.gov
ClinicalTrials.gov Menu

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02591199
Recruitment Status : Terminated (Prematurely terminated based on interim study analysis)
First Posted : October 29, 2015
Last Update Posted : July 11, 2018
Sponsor:
Information provided by (Responsible Party):
Urigen

Brief Summary:
The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder Pain Syndrome. The study is randomized and double-blinded such that neither the subject nor doctor will know which drug or placebo is received.

Condition or disease Intervention/treatment Phase
Interstitial Cystitis Bladder Pain Syndrome Drug: URG101 Drug: Placebo Drug: Lidocaine Drug: Heparin Phase 2

Detailed Description:

This is a Phase 2a, randomized, double-blind, placebo controlled, multicenter, single-dose, pharmacokinetic study designed to determine the efficacy and safety of the combination product (URG101) compared with its individual components (Heparin Sodium and Lidocaine Hydrochloride).

Eligible subjects exhibiting moderate to severe symptoms of bladder pain associated with their diagnosis of interstitial cystitis/bladder pain syndrome who have signed informed consent, will be screened and provisionally enrolled for intravesical treatment.

On the day of study drug administration subjects will be randomized (2:1:2:1; URG101:placebo:lidocaine:heparin) and will receive a single administration of one of four intravesical treatments in a blinded fashion, based on random assignment:

  1. URG101 (buffered lidocaine-heparin)
  2. Placebo (phosphate buffer)
  3. Lidocaine hydrocholoride buffered alone
  4. Heparin sodium buffered alone

Efficacy and safety assessments will be completed for 24 hours after study drug administration. End of Study Follow-up will be completed by telephone 48 to 72 hours after study drug administration.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Study Start Date : September 2015
Actual Primary Completion Date : May 14, 2018
Actual Study Completion Date : June 18, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: URG101
A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
Drug: URG101
Placebo Comparator: Placebo
A single 15 mL dose of placebo delivered to the bladder via catheter.
Drug: Placebo
Experimental: Lidocaine
A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
Drug: Lidocaine
Experimental: Heparin
A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
Drug: Heparin



Primary Outcome Measures :
  1. Change in bladder pain differences from baseline as determined by using the Visual Analog Scale (VAS) [ Time Frame: 24 hours ]
    The primary objective is to evaluate the change in bladder pain intensity differences from baseline to either 12 hours or 24 hours after administration of URG101 compared with the administration of lidocaine alone, heparin alone, and placebo as determined by using the Visual Analog Scale (VAS).


Secondary Outcome Measures :
  1. Change in urgency from baseline as determined using the VAS [ Time Frame: 24 hours ]
    Evaluate the change in urgency intensity differences from baseline to 12 or 24 hours after administration of URG101 compared to lidocaine alone, heparin alone, and placebo using the VAS.

  2. The relationship of plasma lidocaine concentrations at 1 hour after study drug administration to bladder pain and urgency [ Time Frame: 24 hours ]
    Evaluate the relationship of plasma lidocaine concentrations at 1 hour after study drug administration to bladder pain and urgency at 1 hour, and from baseline to 12 and 24 hours after treatment with URG101 compared to lidocaine alone, heparin alone, and placebo.

  3. Safety and tolerability of study medication (Adverse events) [ Time Frame: Up to 72 hours ]
    Adverse events reported after treatment with URG101 compared to lidocaine alone, heparin alone, and placebo.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects diagnosed with interstitial cystitis/bladder pain syndrome must meet all of the following criteria to participate in the study:

  1. Have provided written informed consent to participate in this trial
  2. Be male or female, ≥ 18 years of age
  3. Have moderate-to-severe symptoms of bladder pain of bladder origin for at least 9 months prior to the study
  4. May or may not have received a cystoscopy in association with their diagnosis of interstitial cystitis/bladder pain syndrome prior to or at time of screening
  5. Have a score of ≥ 15 and < 30 on the PUF questionnaire, completed at screening
  6. A minimum score of 5 is required on the VAS
  7. Have been using a stable dose of hormone therapy for ≥ 3 months, if female and currently taking hormone therapy

Exclusion Criteria:

  1. Pregnant or breastfeeding. For females of child bearing potential and males, if sexually active, must be willing to commit to an acceptable method of birth control for the duration of the study.
  2. Have a known hypersensitivity to heparin or lidocaine
  3. Have used any local anesthetic by any route within 24 hours prior to study drug administration, or used a lidocaine patch within 14 days prior to study drug administration
  4. Have used a tricyclic antidepressant or a gamma-Aminobutyric acid (GABA) analogue (gabapentin or pregabalin) unless taking the medication for ≥ 3 weeks. The stable dose of gabapentin may not exceed 1,200 mg per day, and the stable dose of pregabalin may not exceed 150 mg per day.
  5. Have used any pain medication within 6 hours prior to study drug administration
  6. Have used narcotics or medical marijuana ≤ 3 weeks prior to study entry (generic names: fentanyl, hydrocodone, hydromorphone, levorphanol, medical marijuana, methadone, morphine, oxycodone, propoxyphene, tramadol). Subjects who have received codeine within this time period may be admitted if the use is not chronic, and not within 6 hours of enrollment, such that they are not at risk for GI or opiate withdrawal symptoms that in the opinion of the investigator would impact the subject's study participation due to their ability to follow the study protocol or bias study results.
  7. Have used prohibited drugs as determined by self-report, positive urine drug screen, or in the opinion of the investigator be under the influence of drugs affecting mentation precluding their ability to follow the study protocol or bias study results
  8. Have a known clinically significant abnormal laboratory test value defined by the investigator
  9. Have a neurogenic bladder or other disorder that, in the opinion of the investigator, may cause neurogenic bladder (including Parkinson's disease, multiple sclerosis, epilepsy, myasthenia gravis, movement disorders, spinal cord damage)
  10. Have pain or a pain disorder that, in the opinion of the investigator, would make it difficult to discriminate pelvic pain of bladder origin from the other pain
  11. Have severe depression, bipolar disorder, schizophrenia, anxiety, attention deficit disorder, obsessive compulsive disorder, or other major central nervous system disorder
  12. Have history of arrhythmias, conduction disturbances, or cardiac disease, or any coexisting medical condition that, in the opinion of the investigator, may be significant or interfere with study procedures or interpretation of study results
  13. Had bladder instillation therapy within 7 days prior to study entry or had a prior bladder instillation with heparin and lidocaine and did not respond
  14. Had dilatation (hydrodistention) of bladder within 3 months of study entry
  15. Evidence or suspected presence of cancer detected during cystoscopy prior to or at time of initial screening.
  16. Has received any investigational drug or device within 30 days prior to screening
  17. Is currently enrolled in another investigational drug or device study
  18. Is unwilling or unable to abide by the requirements of the study
  19. Have an actively bleeding lesion or area in the bladder as detected by dipstick urinalysis and investigator assessment, immediately prior to randomization
  20. Have had any of the following: bacterial, chemical (including ketamine and cyclophosphamide) or radiation cystitis; gynecological, urological or rectal cancer; current chemotherapy; tuberculous cystitis; urinary schistosomiasis; bladder or uretal calculi; vaginitis or genital herpes; urethral diverticulum or bladder fistulae.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02591199


Locations
United States, California
IC Study, LLC
Escondido, California, United States, 92025
University of California San Diego
San Diego, California, United States, 92103
United States, Georgia
Georgia Urology
Cartersville, Georgia, United States, 30120
United States, Kansas
The Urogynecology Center
Overland Park, Kansas, United States, 66209
United States, New Jersey
Rutgers Women's Health Clinic
New Brunswick, New Jersey, United States, 08901
United States, New York
The Arthur Smith Institue for Urology- North Shore Long Island Jewish Health System
Lake Success, New York, United States, 11042
United States, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
MetroHealth System, Center for Advanced Gynecology
Cleveland, Ohio, United States, 44109
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, South Dakota
Sanford Research
Sioux Falls, South Dakota, United States, 57105
United States, Virginia
Urology of Virginia, PLLC
Virginia Beach, Virginia, United States, 23462
Sponsors and Collaborators
Urigen
Investigators
Study Chair: C. Lowell Parsons, MD Urigen

Additional Information:
Responsible Party: Urigen
ClinicalTrials.gov Identifier: NCT02591199     History of Changes
Other Study ID Numbers: URG101-105
First Posted: October 29, 2015    Key Record Dates
Last Update Posted: July 11, 2018
Last Verified: July 2018

Additional relevant MeSH terms:
Syndrome
Somatoform Disorders
Cystitis
Cystitis, Interstitial
Disease
Pathologic Processes
Mental Disorders
Urinary Bladder Diseases
Urologic Diseases
Lidocaine
Calcium heparin
Heparin
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents